196 related articles for article (PubMed ID: 22369302)
1. The expression of CXCR3 and CD30 in mycosis fungoides.
Nikoo A
Arch Iran Med; 2012 Mar; 15(3):146-50. PubMed ID: 22369302
[TBL] [Abstract][Full Text] [Related]
2. The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides.
Lu D; Duvic M; Medeiros LJ; Luthra R; Dorfman DM; Jones D
Am J Clin Pathol; 2001 Mar; 115(3):413-21. PubMed ID: 11242798
[TBL] [Abstract][Full Text] [Related]
3. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
4. Mycosis fungoides with focal CD 30 transformation in an adolescent.
Romero M; Haney M; Desantis E; Zlotoff B
Pediatr Dermatol; 2008; 25(5):565-8. PubMed ID: 18950403
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.
Talpur R; Sui D; Gangar P; Dabaja BS; Duvic M
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):49-56. PubMed ID: 26702474
[TBL] [Abstract][Full Text] [Related]
6. Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease.
Vermeer MH; Geelen FA; Kummer JA; Meijer CJ; Willemze R
Am J Pathol; 1999 Apr; 154(4):1203-10. PubMed ID: 10233858
[TBL] [Abstract][Full Text] [Related]
7. Mycosis fungoides with spontaneously regressing CD30-positive tumorous lesions.
Woodrow SL; Basarab T; Russell Jones R
Clin Exp Dermatol; 1996 Sep; 21(5):370-3. PubMed ID: 9136160
[TBL] [Abstract][Full Text] [Related]
8. Correlations between clinical and pathological features in 17 cases of mycosis fungoides before and after transformation.
Bittencourt AL; Oliveira PD; Carvalho-Andrade A; Araújo I
Int J Dermatol; 2015 Sep; 54(9):e327-31. PubMed ID: 26147565
[TBL] [Abstract][Full Text] [Related]
9. Papular mycosis fungoides: report of two patients, literature review, and conceptual re-appraisal.
Noe MH; Drake A; Link BK; Liu V
J Cutan Pathol; 2013 Aug; 40(8):714-9. PubMed ID: 23651057
[TBL] [Abstract][Full Text] [Related]
10. Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay.
Yagi H; Seo N; Ohshima A; Itoh T; Itoh N; Horibe T; Yoshinari Y; Takigawa M; Hashizume H
Am J Surg Pathol; 2006 Sep; 30(9):1111-9. PubMed ID: 16931956
[TBL] [Abstract][Full Text] [Related]
11. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
[TBL] [Abstract][Full Text] [Related]
12. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
[TBL] [Abstract][Full Text] [Related]
13. A case of CD30+ large-cell transformation in a patient with unilesional patch-stage mycosis fungoides.
Ohtani T; Kikuchi K; Koizumi H; Kunii T; Aiba S
Int J Dermatol; 2009 Jun; 48(6):623-6. PubMed ID: 19538373
[No Abstract] [Full Text] [Related]
14. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
15. Transformed mycosis fungoides: clinicopathological features and outcome.
Barberio E; Thomas L; Skowron F; Balme B; Dalle S
Br J Dermatol; 2007 Aug; 157(2):284-9. PubMed ID: 17573879
[TBL] [Abstract][Full Text] [Related]
16. Mycosis fungoides with CD30-positive cells in the epidermis.
Wu H; Telang GH; Lessin SR; Vonderheid EC
Am J Dermatopathol; 2000 Jun; 22(3):212-6. PubMed ID: 10871063
[TBL] [Abstract][Full Text] [Related]
17. Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation.
Raghavan SS; Hong EK; Kim YH; Kim J
J Cutan Pathol; 2019 Jan; 46(1):33-43. PubMed ID: 30328119
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
19. CCR7 expression correlates with subcutaneous involvement in mycosis fungoides skin lesions and promotes migration of mycosis fungoides cells (MyLa) through mTOR activation.
Hu SC; Lin CL; Hong CH; Yu HS; Chen GS; Lee CH
J Dermatol Sci; 2014 Apr; 74(1):31-8. PubMed ID: 24411580
[TBL] [Abstract][Full Text] [Related]
20. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior.
Vermeer MH; van Doorn R; Dukers D; Bekkenk MW; Meijer CJ; Willemze R
J Clin Oncol; 2001 Dec; 19(23):4322-9. PubMed ID: 11731515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
